— Trastuzumab emtansine (T-DM1) EMILIA Phase III data selected
for plenary session; SAR3419 data and additional trastuzumab emtansine
data also being reported —
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted
antibody-based anticancer products, today announced that there will be
four presentations at the upcoming 2012 American College of Clinical
Oncology (ASCO) Annual Meeting on compounds that utilize the Company's
Targeted Antibody Payload (TAP) technology. Of particular note, the
findings in the trastuzumab emtansine EMILIA Phase III trial will be
featured in an ASCO plenary session on June 3, and findings with SAR3419
administered with its Phase II dosing schedule will be reported in a
poster presentation on June 4, 2012. Trastuzumab emtansine and SAR3419
are in development by Roche and Sanofi, respectively, under agreements
with ImmunoGen.
"ASCO's decision to feature the EMILIA data in a plenary session speaks
to the significance they attach to the findings," commented Daniel
Junius, President and CEO. "We developed our TAP technology to enable
the creation of better anticancer therapies, and the data reported to
date with trastuzumab emtansine support that it can offer meaningful
efficacy and tolerability advantages. On June 6 the body of data for
trastuzumab emtansine will advance to a new level with the presentation
of the findings from its first Phase III trial."
Mr. Junius continued, "There are many other TAP compounds advancing
through both our own product programs and those of our partners. We're
particularly pleased that Phase I data with SAR3419 administered with
its Phase II dosing schedule also will be reported at ASCO. While
trastuzumab emtansine helps demonstrate the significance of our
technology in a solid tumor indication, SAR3419 is well positioned to
help demonstrate this in liquid tumor indications."
Trastuzumab Emtansine Presentations
-
June 2, Breast Cancer - HER2/ER Poster Discussion Session, Display:
1:15 - 5:15 pm in E450a. Discussion: 4:45 - 5:45 PM in E Hall D2.
"Results
from a phase Ib study of trastuzumab emtansine, paclitaxel, and
pertuzumab in patients with HER2-positive metastatic breast cancer
previously treated with trastuzumab." Abstract #528. Poster Board #18.
Presenter: Shanu Modi, MD.
"Cardiac safety in a phase II
study of trastuzumab emtansine following anthracycline-based
chemotherapy as adjuvant or neoadjuvant therapy for early-stage
HER2-positive breast cancer." Abstract #532. Poster Board #22.
Presenter: Chau T. Dang, MD.
-
June 3, Plenary Session, in N Hall B1
1:45 - 2:00 pm
"Primary results from EMILIA, a phase III study of trastuzumab
emtansine versus capecitabine and lapatinib in HER2-positive locally
advanced or metastatic breast cancer previously treated with
trastuzumab and a taxane." Abstract #LBA1. Presenter: Kimberly L.
Blackwell, MD.
2:00 - 2:15 pm Discussion. Discussant: Louis
M. Weiner, MD.
SAR3419 Presentation
-
June 4, Lymphoma and Plasma Cell Disorders General Poster Session,
1:15 - 5:15 pm in S Hall A2.
"Phase I study cohort
evaluating an optimized administration schedule of SAR3419, an
anti-CD19 DM4-loaded antibody drug conjugate, in patients with
CD19-positive relapsed/refractory b-cell non-Hodgkin's lymphoma
(NCT00796731)." Abstract #8057. Poster Board: #33F. Presenter:
Bertrand Coiffier, MD, PhD.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's TAP
technology uses monoclonal antibodies to deliver one of ImmunoGen's
proprietary cancer-cell killing agents specifically to tumor cells.
There are now numerous TAP compounds in clinical development with a
wealth of clinical data reported. ImmunoGen's collaborative partners
include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and
Sanofi. The most advanced compound using ImmunoGen's TAP technology,
trastuzumab emtansine (T-DM1), is in Phase III testing through the
Company's collaboration with Genentech, a member of the Roche Group.
More information about ImmunoGen can be found at www.immunogen.com.
This press release includes forward-looking statements. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities Litigation
Reform Act of 1995. It should be noted that there are risks and
uncertainties related to the development of novel anticancer products,
including trastuzumab emtansine and SAR3419, including risks related to
clinical studies and their results. A review of these risks can be found
in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June
30, 2011 and other reports filed with the Securities and Exchange
Commission.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media